Emvision Medical Devices Ltd

Research Emvision Medical Devices Ltd (EMV) on Bullrun: market cap AUD 150.59M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is AUD 150.59M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025n/a-AUD 9.81M-AUD 7.89Mn/a-0.11AUD 10.46MAUD 3.53MAUD 9.28M
FY2024n/a-AUD 2.73M-AUD 6.29Mn/a-0.03AUD 18.60MAUD 2.90MAUD 18.52M
FY2023n/a-AUD 3.87MAUD 646.86Kn/a-0.05AUD 9.97MAUD 3.04MAUD 5.12M
FY2022n/a-AUD 6.11M-AUD 3.97Mn/a-0.08AUD 6.80MAUD 737.86KAUD 7.08M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-06AUD 150.59Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 AUD.

About Emvision Medical Devices Ltd

EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia. It offers non invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients. The company was incorporated in 2017 and is based in Macquarie Park, Australia.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Emvision Medical Devices Ltd's market cap?

Emvision Medical Devices Ltd's market capitalization is AUD 150.59M.

What does Emvision Medical Devices Ltd do?

EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia. It offers non invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients. The company was incorporated in 2017 and is based in Macquarie Park, Australia.